Genomic profiles and treatment outcomes in young adults with stage IV non-small cell lung cancer (NSCLC): Insights from the Middle East. Distribution of pathogenic mutations in NSCLC patients (N = 72) ...

Despite the significance of immune checkpoint inhibitors (ICIs) in solid tumor treatment, identifying ICI-sensitive populations remains a challenge. Mutations in DNA damage response (DDR) pathway ...

A study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene mutation behaves differently from other variants. The study, published in Cancer ...

In an effort to foster progress in cancer research, the National Institute of Standards and Technology (NIST) is releasing detailed and comprehensive data about the entire genetic content of a ...

Researchers at the University of Oslo and Oslo University Hospital have developed a promising new immunotherapy targeting the CTNNB1 gene mutation associated with various aggressive cancers like lung ...

Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control. The American Society of Clinical Oncology (ASCO) released updated treatment ...

World Cancer Day 2026 – united by unique: Cell lines for national and international cancer research – Leibniz Institute DSMZ cell line collection ...

The Trade-off Between Physiological Authenticity and Experimental Convenience: Navigating the Cellular Foundation of ...

In mantle cell lymphoma (MCL), an aggressive form of B-cell non-Hodgkin lymphoma, TP53 mutations are known to affect patients’ prognosis—but questions remain. What does the heterogeneity of TP53 ...

Hyderabad are advancing cancer research by integrating genomics, epigenetics, gene regulation and artificial intelligence to ...